[7] Noda K, Saad Y, Karnik SS. Interaction of Phe8 of angiotensin II with
Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem
1995;270:28511–4.
[8] Han HMCB, Shimuta SI, Kanashiro CA, Oliveira L, Han SW, Paiva ACM.
Residues Val254, His256, and Phe259 of the angiotensin II AT1 receptor
are not involved in ligand binding but participate in signal transduction.
Mol Endocrinol 1998;12:810–4.
[9] Ohyama K, Yamano Y, Sano T, Nakagomi Y, Wada M, Inagami T. Role of
the conserved DRY motif on G protein activation of rat angiotensin II
receptor type 1A. Biochem Biophys Res Commun 2002;292:362–7.
[10] Wang C, Jayadev S, Escobedo JA. Identification of a domain in the
angiotensin II type 1 receptor determining Gq coupling by the use receptor
chimera. J Biol Chem 1995;270:16677–82.
[11] Hunyady L, Bor M, Baukal AJ, Balla T, Catt KJ. A conserved NPLFY
sequence contributes to agonist binding and signal transduction but not an
internalization signal for the type 1 angiotensin II receptor. J Biol Chem
1995;270:16602–9.
[12] S, Perlman, H.T. Schambye, R.A. Rivero, W.J. Greenlee, S.A. Hjorth, and
T.W. Schwartz, Non-peptide angiotensin agonist. Functional and molec-
ular interaction with the AT1 receptor, J Biol Chem 270, pp. 1493–1496.
[13] Costa-Neto CM, Miyakawa AA, Pesquero JB, Oliveira L, Hjorth SA,
Schwartz TW, Paiva AC. Interaction of a non-peptide agonist with angiotensin
II AT1 receptor mutants. Can J Physiol Pharmacol 2002;80:413–7.
[14] Leung PS. The peptide hormone angiotensin II: its new functions in tissues
and organs. Curr Protein Pept Sci 2004;54:267–73.
[15] Haulica I, Bild W, Serban DN. Angiotensin peptides and their pleiotropic
actions. J Renin Angiotensin Aldosterone Syst 2005;6:121–31.
[16] Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz
J Med Biol Res 2005;38:499–507.
[17] Santos RA, Simoes-Silva AC, Maric C, Silva DM, Machado RP, Buhr I,
Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos
VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T.
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled
receptor Mas. Proc Natl Acad Sci U S A 2003;100:8258–63.
[18] Pinheiro SV, Simoes e Silva AC, Sampaio WO, de Paula RD, Mendes EP,
Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M, Bleich M,
Santos RA. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas
agonist in the mouse kidney. Hypertension 2004;4:490–6.
[19] Rabin M, Birnbaum D, Young D, Birchmeier C, Wigler M, Ruddle FH.
Human ros1 and mas1 oncogenes located in regions of chromosome 6
associated with tumor-specific rearrangements. Oncogene Res 1987;1:
169–78.
[20] Young D, O'Neill K, Jessell T, Wigler M. Characterization of the rat mas
oncogene and its high-level expression in the hippocampus and cerebral
cortex of rat brain. Proc Natl Acad Sci U S A 1988;85:5339–42.
[21] Zohn IE, Symons M, Chrzanowska-Wodnicka M, Westwick JK, Der CJ.
Mas oncogene signaling and transformation require the small GTP-binding
protein Rac. Mol Cell Biol 1998;18:1225–35.
[22] Jackson TR, Blair AC, Marshall J, Goedert M, Hanley MR. The mas
oncogene encodes an angiotensin receptor. Nature 1988;335:437–40.
[23] Ambroz C, Clark AJ, Catt KJ. The mas oncogene enhaces angiotensin-
induced [Ca2+]i responses in cells with pre-existing angiotensin II
receptors. Biochim Biophys Acta 1991;1133:107–11.
[24] Ardaillou RJ. Angiotensin II receptors. J Am Soc Nephrol 1999;10:30–9.
[25] Von Bohlen und Halbach O, Walther T, Bader M, Albrecht DJ. Interaction
between Mas and the angiotensin AT1 receptor in the amygdale.
Neurophysiol 2000;83:2012–21.
[26] Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-
Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P,
Schultheiss HP, Walther T. G-protein-coupled receptor Mas is a
physiological antagonist of the angiotensin II type 1 receptor. Circulation
2005;111:1806–13.
[27] Canals M, Jenkins L, Kellett E, Milligan G. Up-regulation of the angiotensin
II type 1 receptor by the MAS proto-oncogene is due to constitutive activation
of Gq/G11 by MAS. J Biol Chem 2006;281:16757–67.
[28] Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP.
Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with
AT1 and AT2 receptors in the mouse heart. Hypertension 2005;46:937–42.
[29] Cverjic S, Devi LA. Dimerization of thr δ-opioid receptor: implication for
a role in receptor internalization. J Biol Chem 1997;272:26959–64.
[30] Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A, Griffon N,
Corsini GU, Sokoloff P, Levenson R, Vogel Z, Maggio R. D2/D3 dopamine
receptor heterodimers exhibit unique functional properties. J Biol Chem
2001;276:30308–14.
[31] Maggio R, Barbier P, Colelli A, Salvadori F, Demontis G, Corsini GU.
G protein-linked receptors: pharmacological evidence for the formation of
heterodimers. J Pharmacol Exp Ther 1999;291:251–7.
[32] Xu J, He J, Castleberry AM, Balasubramanian S, Lau AG, Hall RA.
Heterodimerization of α2A- and β1-adrenergic receptors. J Biol Chem
2003;278:10770–7.
[33] Ramsay D, Kellett E, McVey M, Rees S, Milligan G. Homo- and hetero-
oligomeric interactions between G-protein-coupled receptors in living
cells monitored by two variants of bioluminescence resonance energy
transfer (BRET): hetero-oligomers between receptor subtypes form more
efficiently than between less closely related sequences. Biochem J
2002;365:429–40.
[34] AbdAlla S, Zaki E, Lother H, Quitterer U. Invol vement of the amino
terminus of the B(2) receptor in agonist-induced receptor dimerization.
J Biol Chem 1999;274:26079–84.
[35] Monnot C, Bihoreau C, Conchon S, Curnow KM, Corvol P, Clauser E. Polar
residues in the transmembrane domains of the type 1 angiotensin II receptor
are required for binding and coupling. J Biol Chem 1996;271:1507–13.
[36] AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show
enhanced G-protein activation and altered receptor sequestration. Nature
2000;407:94–8.
[37] AbdAlla S, Lother H, Abdel-Tawab AM, Quitterer U. Increased AT1
receptor heterodimers in preeclampsia mediate enhanced angiotensin II
responsiveness. Nat Med 2001;7:1003–9.
[38] AbdAlla S, Lother H, Abdel-Tawab AM, Quitterer U. The angiotensin II AT2
receptor is an AT1 receptor antagonist. J Biol Chem 2001;276:39721–6.
[39] Johansen TE, Scholer MS, Tolstoy S, Schwartz TW. Biosynthesis of
peptide precursors and protease inhibitors using new constitutive and
inducible eukariotic expression vectors. FEBS Lett 1990;267:289–94.
[40] Gether U, Johansen TE, Schwartz TW. Chimeric NK
1
(substance P)/NK
3
(neurokinin B) receptors — identification of domains determining the
binding specificity of tachykinin. J Biol Chem 1993;268:7893–8.
[41] Kanashiro CA, Paiva TB, Paiva A C, Prioste RN, Aboulafia J, Shimuta
SI. A ngiotensin II tachyphylaxis in the guinea pig ileum and its pre-
vention: a pharmacological and biochemical study. J Pharmacol Exp Ther
1995;275:1543–50.
[42] Milligan G. G protein-coupled receptor dimerization: function and ligand
pharmacology. Mol Pharmacol 2004;66:1–7.
[43] Walther T, Balschun D, Voigt JP, Fink H, Zuschrater W, Birchmeier C,
Ganten D, Bader M. Sustained long-term potentiation and anxiety in mice
lacking the Mas protooncogene. J Biol Chem 1998;273:11867–73.
[44] Le MT, De Backer JP, Hunyady L, Vanderheyden PM, Vauquelin G. Ligand
binding and functional properties of human angiotensin AT1 receptors in
transiently and stably expressed CHO-K1 cells. Eur J Pharmacol
2005;513:35–45.
[45] Horiuchi M, Lehtonen JYA, Daviet L. Signaling mechanism of the AT
2
angiotensin II receptor: crosstalk between AT
1
and AT
2
receptors in cell
growth. Trends Endocrinol Metab 1999;10:391–6.
[46] Werry TD, Wilkinson GF, Willars GB. Mechanisms of cross-talk between
G-protein-coupled receptors resulting in enhanced release of intracellular
Ca
2+
. Biochem J 2003;374:281–96.
[47] Dixon BS, Sharma RV, Dickerson T, Fortune J. Bradykinin and
angiotensin II: activation of protein kinase C in arterial smooth muscle.
Am J Physiol 1994;266:C1406–20.
[48] Zhuo J, Dean R, Maric C, Aldred PG, Harris P, Alcorn D, Mendelsohn FA.
Localization and interactions of vasoactive peptide receptors in renome-
dullary interstitial cells of the kidney. Kidney Int 1998;67:22–8.
[49] Breitwieser GE. G protein-coupled receptor oligomerization: implications
for G protein activation and cell signaling. Circ Res 2004;94:17–27.
[50] Wojcik J, Berg MA, Esposito N, Geffner ME, Sakati N, Reiter EO, Dower
S, Francke U, Postel-Vinay MC, Finidori J. Four contiguous amino acid
substitutions, identified in patients with Laron syndrome, differently affect
166 E.L. Santos et al. / Regulatory Peptides 141 (2007) 159–167